Overall Performance
Concordance: 433 results were obtained from pregnant women to assess positive and negative agreements
relative to a reference methodology.† The BioPlex™ 2200 Syphilis IgG kit shows excellent correlation with the
reference method.
† Reference Assay: Combined results from commercially available RPR and TPPA assays. For discrepant results (between RPR and TPPA),
a commercial treponemal EIA test was used for final interpretation.
Serum Samples Requested to Be Treponemal Positive | BioPlex 2200 Syphilis IgG |
| Reactive | Equivocal | Nonreactive | Total | Positive (+) % Agreement | 95% Confidence Interval |
Reference Assay Result | Positive | 166 | 0 | 0 | 166 | 100% (166/166) | 97.7–100% |
| Equivocal | 4* | 0 | 0 | 4 |
| Negative | 8** | 0 | 5 | 13 |
| Total | 178 | 0 | 5 | 183 |
* Four (4) BioPlex 2200 Syphilis IgG reactive samples were RPR nonreactive, TPPA reactive, and treponemal EIA equivocal.
** Of eight (8) BioPlex 2200 Syphilis IgG reactive samples, 7 were RPR nonreactive, TPPA reactive, and treponemal EIA negative and
1 sample was RPR and TPPA nonreactive.
Serum Samples Requested to Be RPR and TPPA NonReactive | BioPlex 2200 Syphilis IgG |
| Reactive | Equivocal | Nonreactive | Total | Negative (–) % Agreement | 95% Confidence Interval |
Reference Assay Result | Positive | 0 | 0 | 0 | 0 | 98.8% (247/250) | 96.5–99.6% |
| Equivocal | 0 | 0 | 0 | 0 |
| Negative | 3* | 0 | 247 | 250 |
| Total | 3 | 0 | 247 | 250 |
* Three (3) BioPlex 2200 Syphilis IgG reactive samples were RPR and TPPA nonreactive.